Coronavirus is providing opportunities for investors beyond well-known names. A good example is a stock that most investors have never heard of but have provided 38% return to The Arora Report subscribers in a short time. More gains are likely ahead. The following post was published earlier on ZYX Buy.
MORE GAINS AHEAD IN BIOTECH MRVI — SUPPLIER OF A KEY COMPONENT OF CORONAVIRUS VACCINE
Maravai LifeSciences (MRVI) is long from $25.84. MRVI is trading at $35.78 as of this writing. This represents a gain of 38% in a short time.
We have previously written that the target zone was likely to be raised.
MRVI supplies a key component of the coronavirus vaccine produced by Pfizer (PFE) and BioNTech (BNTX). The vaccine should provide a sharp increase in revenue. The company also has a diversified product portfolio.
For those following the Good Way, the Buy Now rating is ‘NO.’
For those following the Best Way the buy zone is $26.11 to $31.31.
The stop zone is $21.38 to $22.33. The new first target zone is $48 to $52. The new second target zone is $73 to $78 if it catches the momo crowd’s attention. The maximum quantity is 30% of full core position size.
What To Do Now
Those in the stock and have taken partial profits may consider continuing to hold.
Those not in the stock may consider following the parameters above or wait for a new signal with a different buy zone.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.